Skip to main content
Equibles
ALMS logo

ALMS · Alumis Inc.

Track ALMS — free

Use ALMS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALMS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$22.38 -0.83 (-3.58%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$2.90B
Shares
129.44M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$22.38 Open$22.83 Day$22.35–23.28 52W close$3.95–30.30 Avg vol 30d861K Short int5.9M · 4.5% float · 6.5d Short vol65% Last earningsMay 14, 2026 DataJun 2024–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.39
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −16%
below
RSI (14) 38
neutral
MACD trend Negative
52-week position 70%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −21%
trailing
6-month return −17%
trailing
YTD return +129%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $26 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +29 funds added
Insider flow Distributing
Net -$534.3K over 90 days · 100% sells
Short interest Rising
4.52% of float · ▲ +1.5% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
201 holders — near 2-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Fair
EPS growth +72%
Y/Y
Free cash flow $-370.2M
Quant / Vol
risk profile
Very High
Volatility 122%
annualized · 1-yr
Max drawdown −37%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−16% Bearish
RSI (14)
38 Neutral
MACD trend
Negative Bearish
52-week position
70% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $26 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +29 funds added
Insider flow Distributing
Net -$534.3K over 90 days · 100% sells
Short interest Rising
4.52% of float · ▲ +1.5% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
201 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $22 · 70% Range high $30
vs 200-day avg +2% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross proceeds to Alumis from the offering $345.1M January 2026 —
net proceeds of $324.4 million, after underwriting discounts and commissions, from its public of $324.4M January 2026 —
patients achieving PASI 100 40% Week 24, on average —
patients achieving PASI 90 65% Week 24, on average —
shares of its common stock 20,297,500 January 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALMS
Alumis Inc.
this stock
$2.90B +129.3% — — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
201
% held
92.0%
Net QoQ
+3.3M sh
Top holder
AyurMaya Capital Manageme…
Held Float
View
Held by Funds
Fund positions
201
View
Short & Settlement
Short Interest Rising
Shares short
5.9M
Days to cover
6.5d
Change
+87.8K sh
View
Short Volume
Short vol %
65%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$27
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$534.3K
Buyers / Sellers
0 / 6
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$24.1M
Net income (FY)
$-243.3M
EPS diluted
$-2.86
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
14
View
Proposed Sales
Value
$140.0K
Shares
5.0K
Filed
Jul 6, 2026
View
Exempt Offerings
Offering
$40.0M
Filed
Jul 24, 2024
View
Earnings & Events
Earnings Calls
Last call
May 14, 2026
View

Performance

5D 20D 120D MTD YTD
ALMS -7.4% -20.8% -16.6% -20.8% +129.3%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -7.9% -23.8% -30.1% -23.8% +116.5%
Key facts CIK 1847367 CUSIP 022307102 13F (30d) 178 filings 176 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)